전립선암에 대한 방사선치료

Radiation Treatment for Prostate Cancer

Abstract

electing the optimal treatment of each stage of prostate cancer is very challenging, partly because the options for treatment today are far better than they were ten years ago, but also because not enough reliable data are available on which to base the decisions. Accordingly, scientifically controlled, long - term studies are still needed to compare the benefits and risks of the various treatments. In the process of counseling and discussing therapeutic options with patients with prostate cancer, it is important to present all available data regarding the variable natural history of this disease, prognostic significance of the diagnosis, potential therapeutic benefit of the various modalities, and immediate as well as late treatment - related sequelae. Radiation therapy can be given either as external beam radiation over perhaps 6 or 7 weeks or as an implant of radioactive seeds (brachytherapy) directly into the prostate. In external beam radiation, high energy x - rays are aimed at the tumor and the area immediately surrounding it. In brachytherapy, radioactive seeds are inserted through needles into the prostate gland under the guidance of transrectally taken ultrasound pictures. This article will describe recent advances in external beam radiotherapy (3D conformal radiotherapy (3D - CRT) & Intensity Modulated Radiotherapy (IMRT) J, indications of radiotherapy, response evaluation and assessment of relapse after the radiation treatment for prostate cancer, and radiation - related complications.

Keywords : **Prostate cancer**; **Radiotherapy**; **3D - CRT**; **IMRT** : ; ; 3 ;

가

. 10

가

(Nerve - sparing Surgery)

(1, 2),

2

(2D - Conventional Radiotherapy,


2D - RT) 3

(3 - Dimensional Conformal


Radiotheray, 3D - CRT)

(Intensity Modu-

lated Radiotherapy, IMRT)



```
(A) 20
                                     가
                                                                                       가
     (MLC)
                                             (B)
                                       2.
                                                         (IMRT)
      가
                                                                                                 가
                                                                     2
                                                                                        , 3
                                                                 Iodine - 125, Palladium - 103
     1).
                                                                  (radioisotope seed)
                          3
 가
             СТ
                                                                                        (
                                                                                             3).
                                                                            Iridium - 192
                                                                   가
                                                               lodine - 125
           가
                                             가
                                                                          가
                                                        3
                                                                                          가
                                        (Multi -
leaf collimator)
                                    2).
                                                   RTOG(Radiation Therapy Oncology Group) Grade 2
```



85%		가 Sta	ge A2(T1b)	10%, Stage B1
(10),	가	(T2a) 18%,	Stage B2(T2b)	50 ~ 60%
		(12, 13),	
,		가		
가		Jewett	Stage C, AJ	CC TNM
~1				CC TIVIVI
•	(2	T3, N0, M0, any G 가		
7.71	(3			
)가	71	,	,	가
	가		3	
5	가	· · · · · · · · · · · · · · · · · · ·	2	
. Richard Pescl	hel John Colberg	,		-1
3				가
т	1c, T2 가	가	가	
•	10, 12	(14, 15)		
, 가				ogy Group(RTOG)
, 3		T2b	on merapy onco	ogy Group(ICTOO)
(11).		120		(Bio-
가 TURP		chemical Failure	<u> </u>	(100-
7) TOKE	4~6	chemical i anure	5)	
	4~0	(16	١	
Indina 105 Dalladiu	102	(16).	
lodine - 125, Palladiu	IIII - 103	가		(harmana ra
			,	(hormone re-
, 71		fractory)		71
가	,	. 가		가
•	, 가			71
가				가 ,
	or B, T1 or T2)			
	e - Sparing)			
(· - [·· · · · · · · · · · ·] /		-	

가 4.7 ng/ml , 3 30 ng/ml PSA (19). PSA **PSA** 0~4(, 1.2) ng/ml, Ritter Zagar 가 0~3.2(1.1) ng/ml PSA 가 (Nadir PSA 가 가 value) 가 **PSA** 가 **PSA** (20), (Nadir PSA value) (17). 3 가 가 5 (Biochemial disease free (Biochemical failure, PSA rising) survival), **PSA** 가 **PSA** (Nadir PSA value) 5 가 **PSA** 가 (11). **PSA** (17). 가 **PSA** 0.2 ng/ml (21). (Sexual potency) PSA 가 (21). (TURP) 4~6 **PSA** 가 . Ritter (22). 가 **PSA** 가 가 가 PSA 가 가 43 58.5 (18). Zagar

1.

		+	+++	+				
		+++	++	+				
					,			
		+++	+	+	•			
		+	+	+++				
						,		
	가		가		, Gleason Score, PAS	· ·		
	·	(rotontion			,	, 가		
	,	(retention)		,	71		
			•		, 가			
	Nerve - sparing					.`@		
			,					
(Nerve -	sparing)						
(op a g			가				
				1. Catalona V	VJ, Basler JW. Return of erec	ctions and urinary conti-		
	가		가		owing nerve sparing radical r			
	- 1	,	• 1		1993 ; 150(3) : 905 - 7	etropuble prostatosto		
			•	, and the second		no atata ata may in Malah		
가			1 .		JA, Scardino PT, ed. Radical p	-		
					AB, Vaughan ED, et al., eds			
				8th ed. Phi	iladelphia : WB Saunders, 200)2 : 3080 - 3		
				3. Zelefsky N	/J, Fuks Z, Hunt M, Lee HJ, I	Lombardi D, Leibel SA,		
				et al. High	n dose radiation delivered by	y intensity modulated		
		,	,	conformal	I radiotherapy improves the	outcome of localized		
,		,		prostate ca	prostate cancer. J Urol 2001 ; 166 : 878 - 81			
	,			4. Zelefsky N	4. Zelefsky MJ, Fuks Z, Happersett L, Lee HJ, Ling CC, Leibe			
				SA, et al. (Clinical experience with intens	sity modulated radiation		
		가		therapy (II	MRT) in prostate cancer. Ra	adiother Oncol 2000;		
		•		, 55(3) : 241	- 9			
	,			5. Consensus	5. Consensus conference. The management of clinically locali-			
			(Nerve - sparing	sur- zed prosta	te cancer. JAMA 1987 ; 258(1	19) : 2270 - 30		
gery)	,		СТ	•	I, Paull G, Eggleston JC, Wa			
	3	3			stage A1 prostatic carcinoma	_		
	,				nded followup. J Urol 1986 ; 1:	-		
	,			With CALCII	1000 TO1100 Vap. 5 0101 1700 , 11	33(1). 337		

가

- 7. D'Amico AV, Whittington R, Kaplan I, Beard C, Schultz D, Coleman CN, et al. Equivalent 5 year bNED in select prostate cancer patients managed with surgery or radiation therapy despite exclusion of the seminal vesicles from the CTV. Int J Radiat Oncol Biol Phys 1997; 39(2): 335 40
- Kupelian P, Katcher J, Levin H, Zippe C, Suh J, Klein E, et al. External beam radiotherapy versus radical prostatectomy for clinical stage T1 - 2 prostate cancer: therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores. Cancer J Sci Am 1997; 3(2): 78 - 87
- 9. Zelefsky MJ, Wallner KE, Ling CC, Raben A, Hollister T, Leibel SA, et al. Comparison of the 5 year outcome and morbidity of three dimensional conformal radiotherapy versus transperineal permanent iodine 125 implantation for early stage prostatic cancer. J Clin Oncol 1999; 17(2): 517 22
- Adolfsson J, Steineck G, Whitmore WF Jr. Recent results of management of palpable clinically localized prostate cancer.
 Cancer. 1993; 72(2): 310 - 22
- 11. Peschel RE, Colberg JW. Surgery, brachytherapy, and external beam radiotherapy for early prostate cancer. Lancet Oncol 2003; 4(4): 233 41
- Catalona WJ, Smith DS. 5 year tumor recurrence rates after anatomical radical retropubic prostatectomy for prostate cancer. J Urol 1994 : 152(5 Pt 2) : 1837 - 42
- Gibbons RP. Total prostatectomy for clinically localized prostate cancer: long - term surgical results and current morbidity. NCI Monogr. 1988; (7): 123 - 6
- 14. Babaian RJ, Zagars GK, Ayala AG. Radiation therapy of stage C prostate cancer: significance of Gleason grade to survival. Semin Urol 1990; 8(4): 225 - 31
- del Regato JA, Trailins AH, Pittman DD. Twenty years followup of patients with inoperable cancer of the prostate (stage C)

- treated by radiotherapy : report of a national cooperative study. Int J Radiat Oncol Biol Phys 1993 ; 26(2) : 197 201
- 16. Pilepich MV, Winter K, John MJ, Mesic JB, Sause W, Grignon D, et al. Phase III radiation therapy oncology group (RTOG) trial 86 10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2001; 50(5): 1243 52
- 17. Consensus statement. guidelines for PSA following radiation therapy. American Society for Therapeutic Radiology and Oncology Consensus Panel. Int J Radiat Oncol Biol Phys 1997; 37(5): 1035 - 41
- Ritter MA, Messing EM, Shanahan TG, Potts S, Chappell RJ, Kinsella TJ. Prostate - specific antigen as a predictor of radiotherapy response and patterns of failure in localized prostate cancer. J Clin Oncol 1992; 10(8): 1208 - 17
- Zagars GK, Sherman NE, Babaian RJ. Prostate specific antigen and external beam radiation therapy in prostate cancer.
 Cancer 1991; 67(2): 412 - 20
- 20. Critz FA, Williams WH, Holladay CT, Levinson AK, Benton JB, Shrake PD, et al. Post - treatment PSA < or = 0.2 ng/mL defines disease freedom after radiotherapy for prostate cancer using modern techniques. Urology 1999; 54(6): 968 - 71
- 21. Hamilton AS, Stanford JL, Gilliland FD, Albertsen PC, Stephenson RA, Potosky AL, et al. Health outcomes after external beam radiation therapy for clinically localized prostate cancer: results from the Prostate Cancer Outcomes Study. J Clin Oncol 2001; 19(9): 2517 26
- 22. Seymore CH, el Mahdi AM, Schellhammer PF. The effect of prior transurethral resection of the prostate on post radiation urethral strictures and bladder neck contractures. Int J Radiat Oncol Biol Phys 1986; 12(9): 1597 600